Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-20T16:30:28.386Z Has data issue: false hasContentIssue false
  • English
  • Français

Schizophrenia and diabetes: Epidemiological data

Published online by Cambridge University Press:  16 April 2020

F. Rouillon  and
F. Sorbara
F. Rouillon*
Affiliation:
Service de psychiatric adulte and Inserm U513, hôpital, Sainte-Anne, 1, rue Cabanis, 75014Paris, France
F. Sorbara
Affiliation:
Lilly France, 13, rue Pages, 92158Suresnes cedex, France and Hôpital Charles-Perrens, 121, rue de la Bechade, 33076Bordeaux cedex, France
*
*Corresponding author. E-mail address: jd.guelfi @ ch-sainte-anne.fr (J.D. Guelfi).
Get access

Abstract

The association of diabetes mellitus and mental illness, in particular, schizophrenia, has been remarked upon for over a century. Recentepidemiological studies have shown the age- and sex-matched prevalence of diabetes in patients with schizophrenia to be 1.5–2 times those in the general population. This difference is particularly noticeable in younger patients. The explanation for this finding probably resides in both environmental and biological factors. Patients with schizophrenia tend to be sedentary and have a poor diet, which are both known risk factors for diabetes. However, familial studies have indicated a heritable component to the risk of diabetes in patients with schizophrenia. A number of biological mechanisms have been proposed to explain this, including neuroendocrine changes and neurodevelopmental anomalies, but none are entirely satisfactory. In addition, it has been suggested that treatment with antipsychotic medication may potentially increase the risk of diabetes and account for some of the increased prevalence seen in patients with schizophrenia. It has been suggested that different antipsychotic drugs may differ in their ability to facilitate the emergence of poor glycaemic control in patients with schizophrenia. However, the situation is far from clear and more work is required to accurately assess the potential risk associated with different antipsychotic drugs.

Keywords

SchizophreniaDiabetesEpidemiological data
Type
Research Article
Information
European Psychiatry , Volume 20 , Issue S4 , December 2005 , pp. S345 - S348
Copyright
Copyright © European Psychiatric Association 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alberti, K.G.The clinical implications of impaired glucose tolerance. Diab Med. 1996; 13(11): 927–373.0.CO;2-E>CrossRefGoogle ScholarPubMed
Andrews, R.C.R.Diabetes and schizophrenia: genes or zinc deficiency. Lancet. 1992; 340: 1160CrossRefGoogle ScholarPubMed
Braceland, F.J.Meduna, L.J.Vaichulis, J.A.Delayed reaction of insulin in schizophrenia. Am J Psychiatry. 1945; 102: 108-10CrossRefGoogle Scholar
Brambilla, F.Guastalla, A.Guerrini, A.Riggi, F.Rovere, C.Zanoboni, A., et al.Glucose-insulin metabolism in chronic schizophrenia. Dis Nerv Syst. 1976; 37(2): 98–103Google ScholarPubMed
Bromel, T.Blum, W.F.Ziegler, A.Schulz, E.Bender, M.Fleischhaker, C., et al.Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry. 1998; 3: 76–80CrossRefGoogle ScholarPubMed
Bushe, C.Holt, R.Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl. 2004; 47: S67–S71CrossRefGoogle ScholarPubMed
Casadebaig, F.Philippe, A.Guillaud-Bataille, J.M.Gausset, M.F.Quemada, N.Terra, J.L.Schizophrenic patients: physical health and access to somatic care. Eur Psychiatry. 1997; 12: 289–293CrossRefGoogle ScholarPubMed
Cheta, D.Dumitrescu, C.Georgescu, M.Cocioaba, G.Lichiardopol, R.Stamoran, M., et al.A study on the types of diabetes mellitus in first degree relatives of diabetic patients. Diabete Metab. 1990; 16(1): 11–5Google Scholar
Dixon, L.Weiden, P.Delahunty, J.Goldberg, R.Postrado, L.Lucksted, A., et al.Prevelance on correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000; 26: 903-12CrossRefGoogle Scholar
Finney, G.O.H.Juvenile onset diabetes and schizophrenia?. Lancet. 1989; 334: 1214-5CrossRefGoogle Scholar
Gupta, S.Steinmeyer, C.Frank, B.Madhusoodanan, S.Lockwood, K.Lentz, B., et al.Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Ther. 2003; 10(5): 348–55CrossRefGoogle ScholarPubMed
Hagg, S.Soderberg, S.Ahren, B.Olsson, T.Mjorndal, T.Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry. 2001; 62: 843-8CrossRefGoogle ScholarPubMed
Kasanin, J.The blood sugar curve in mental disease: the schizophrenic (dementia praecox) groups. Arch Neurol Psychiatry. 1926; 16: 414-9CrossRefGoogle Scholar
Kooy, F.H.Hyperglycaemia in mental disorders. Brain. 1919; 42: 214-89CrossRefGoogle Scholar
Lindenmayer, J.P.Czobor, P.Volavka, J.Citrome, L.Sheitman, B.McEvoy, J.P., et al.Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003; 160(2): 290-6CrossRefGoogle ScholarPubMed
Maudsley, H.The pathology of mind. Second part of the physiology and pathology of the mind, recast/enlarged and rewritten. Third edition Macmillan,1879Google Scholar
McKee, H.A.D'Arcy, P.F.Wilson, P.J.Diabetes and schizophrenia-a preliminary study. J Clin Hosp Pharm. 1986; 11: 297–9Google ScholarPubMed
Mukherjee, S.Decina, P.Bocola, V.Saraceni, F.Scapicchio, P.Diabetes Mellitus in schizophrenic patients. Comp Psychiatry. 1996; 37: 68–73CrossRefGoogle ScholarPubMed
Mukerjee, S.Schur, D.B.Reddy, R.Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989; 333: 495CrossRefGoogle Scholar
Regenold, W.T.Thapar, R.K.Marano, C.Gavirneni, S.Kondapavuluru, P.V.Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent ofpsychotropic drug use. J Affect Disord. 2002; 70: 19–26CrossRefGoogle Scholar
Ryan, M.C.M.Thakore, J.H.Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002; 71: 239–57CrossRefGoogle ScholarPubMed
Ryan, M.C.Collins, P.Thakore, J.H.Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003; 1602: 284-9CrossRefGoogle ScholarPubMed
Sernyak, M.J.Leslie, D.L.Alarcon, R.D.Losonczy, M.F.Rosenheck, R.Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002; 159: 561–6CrossRefGoogle ScholarPubMed
Subramaniam, M.Chong, S.A.Pek, E.Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 4852003 345-7CrossRefGoogle ScholarPubMed
Thonnard-Neumann, E.Phenothiazone and diabetes in hospitalised women. Am J Psychiatry. 1956; 29: 827–8Google Scholar
Thonnard-Neumann, E.Phenothiazone and diabetes in hospitalised women. Am J Psychiatry. 1968; 124: 978–82CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.